Prospective Randomized Open Label Study of the Treatment of Therapy-Associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium - (Loop)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by Philipps University Marburg Medical Center.
Recruitment status was Not yet recruiting
Recruitment status was Not yet recruiting
Sponsor:
Philipps University Marburg Medical Center
Collaborator:
Maros Arzneimittel GmbH
Information provided by:
Philipps University Marburg Medical Center
ClinicalTrials.gov Identifier:
NCT00444093
First received: March 6, 2007
Last updated: August 31, 2007
Last verified: August 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Therapy-associated diarrhea during radiation therapy of small pelvis (including enteritis as a result of radiation therapy and enteritis as a result of radiation- and chemotherapy) is a common problem in multimodal cancer therapy. We investigate the therapeutic effect of either loperamide or tinctura opii in therapy- associated diarrhea in patients who receive radiation therapy of the small pelvis with or without chemotherapy.
| Condition | Intervention | Phase |
|---|---|---|
|
Diarrhea Enteritis Cancer |
Drug: Tinctura opii |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | Prospective Randomized Open Label Study of the Treatment of Therapy-Associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium |
Resource links provided by NLM:
Further study details as provided by Philipps University Marburg Medical Center:
Primary Outcome Measures:
- In this study efficacy of loperamide and tincture of opium is linked to the respective proportions of patients where diarrhoea of grade > 2 is successfully averted during (cancer) therapy.
- Should diarrhoea of grade > 2 occur despite the respective drug treatment, the corresponding medicament is assessed as inefficacious in that case.
Secondary Outcome Measures:
- Scores from the EORTC-QLQ-C30
- Body composition data (BMI, proportions of fat and water
| Estimated Enrollment: | 200 |
| Study Start Date: | September 2007 |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- Age ≥ 18 years
- Patients who will undergo a percutaneous radiation therapy in the area of the small pelvis. This includes patients with following malignancies: rectal carcinoma, prostate carcinoma, endometrial carcinoma, cervix carcinoma.
- Diarrhea grade 1 and grade 2 (Classification NCI-CTCAE Version 3.0)
- ECOG-Grade 0-2
- Enlightenment and written declaration of consent to the participation.
Exclusion Criteria:
- Pregnant patients or patients in lactation period.
- Severe dysfunction of liver or kidneys
- Injury or illness of brain e.g. increased intracranial pressure, cerebral arteriosclerosis
- Epilepsy
- Hypersensitivity to components of loperamide or tincture of opium
- Ileus
- Toxic megacolon
- Pseudomembranous colitis/ antibiotic-associated colitis
- Diarrhea associated with fever and bloody stools
- Acute increase of colitis ulcerous or bacterial colitis caused by invasive pathogenes
- Severe respiratory dysfunction or severely limited lung function e.g. bronchial asthma, bronchitis
- Dysfunctional draining of biliary area, biliary colics.
- Concomitant or earlier addiction of alcohol or opiates
- Severe heart disease
- Pheochromocytoma
- Acute hepatic porphyria
- Cor pulmonale
- Morbus Addison
- Severe hypothyroidism
- Organisational problems or circumstances which prevent a complete collection of required data
- Artificial anus
- Participation in a clinical trial within the last 30 days before involvement
- Participation in an other clinical trial at the same time
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00444093
Sponsors and Collaborators
Philipps University Marburg Medical Center
Maros Arzneimittel GmbH
Investigators
| Principal Investigator: | Michael Bieker, MD | center of radiology, departement of radiation therapy, clinical center Giessen and Marburg |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00444093 History of Changes |
| Other Study ID Numbers: | 2006-002948-28, KKS-73-05 |
| Study First Received: | March 6, 2007 |
| Last Updated: | August 31, 2007 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by Philipps University Marburg Medical Center:
|
radiation therapy diarrhea enteritis supportive therapy |
therapy associated diarrhea therapy associated enteritis radiation therapy of the small pelvis |
Additional relevant MeSH terms:
|
Diarrhea Enteritis Signs and Symptoms, Digestive Signs and Symptoms Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |
Intestinal Diseases Loperamide Antidiarrheals Gastrointestinal Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 18, 2013